It does work(in that it demonstrably increases cholesterol efflux) it just didn’t hit top line 90day MACE reduction across the entire trial population. But it possibly does on a subset of the trial population eg. Certain age bracket or other illnesses. Or for certain specific standard of care combinations . They’ve basically said it will take more time to do more data mining to see if there is a group or situation in which it has significant outcomes benefit.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$254.86 |
Change
6.465(2.60%) |
Mkt cap ! $123.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $256.17 | $251.10 | $208.7M | 809.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 42 | $254.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $254.88 | 8 | 2 |
View Market Depth
| Last trade - 11.51am 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |